Jane Street’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-215,500
| Closed | -$4.64M | – | 11543 |
|
|
2025
Q4 | $4.64M | Buy |
215,500
+106,200
| +97% | +$2.06M | ﹤0.01% | 3345 |
|
|
2025
Q3 | $1.67M | Buy |
+109,300
| New | +$1.42M | ﹤0.01% | 5274 |
|
|
2025
Q1 | – | Sell |
-697,500
| Closed | -$7.33M | – | 9396 |
|
|
2024
Q4 | $7.33M | Buy |
697,500
+168,700
| +32% | +$2.05M | ﹤0.01% | 2197 |
|
|
2024
Q3 | $6.94M | Buy |
528,800
+61,800
| +13% | +$941K | ﹤0.01% | 2368 |
|
|
2024
Q2 | $6.57M | Buy |
467,000
+223,400
| +92% | +$3.64M | ﹤0.01% | 2589 |
|
|
2024
Q1 | $4.11M | Buy |
243,600
+101,300
| +71% | +$1.51M | ﹤0.01% | 2921 |
|
|
2023
Q4 | $2.01M | Sell |
142,300
-6,100
| -4% | -$71.7K | ﹤0.01% | 4312 |
|
|
2023
Q3 | $1.53M | Buy |
148,400
+41,600
| +39% | +$557K | ﹤0.01% | 4495 |
|
|
2023
Q2 | $1.76M | Buy |
106,800
+37,900
| +55% | +$493K | ﹤0.01% | 4352 |
|
|
2023
Q1 | $631K | Sell |
68,900
-22,800
| -25% | -$187K | ﹤0.01% | 5913 |
|
|
2022
Q4 | $657K | Buy |
+91,700
| New | +$643K | ﹤0.01% | 5676 |
|
|
2022
Q3 | – | Sell |
-26,600
| Closed | -$65K | – | 9664 |
|
|
2022
Q2 | $65K | Buy |
26,600
+12,200
| +85% | +$50.1K | ﹤0.01% | 8834 |
|
|
2022
Q1 | $98K | Sell |
14,400
-28,700
| -67% | -$197K | ﹤0.01% | 9461 |
|
|
2021
Q4 | $348K | Sell |
43,100
-8,900
| -17% | -$81.3K | ﹤0.01% | 7909 |
|
|
2021
Q3 | $510K | Buy |
+52,000
| New | +$409K | ﹤0.01% | 7248 |
|
|
2021
Q2 | – | Sell |
-21,100
| Closed | -$191K | – | 9750 |
|
|
2021
Q1 | $191K | Buy |
+21,100
| New | +$171K | ﹤0.01% | 8304 |
|
|
2020
Q3 | – | Sell |
-11,700
| Closed | -$95K | – | 7125 |
|
|
2020
Q2 | $95K | Buy |
+11,700
| New | +$103K | ﹤0.01% | 6719 |
|
Other funds holding AVDL
Jane Street's AVDL Position: Q1 2026 in Review
Jane Street sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 500,561 shares — an estimated $10.8M sold.
Jane Street first reported a position in AVDL in Q2 2014 and held it in 20 quarters. The position peaked at $10.8M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Jane Street reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Jane Street sold 500,561 Avadel Pharmaceuticals shares in Q1 2026, an estimated $10.8M.
- Jane Street first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 20 quarters.
- Jane Street's Avadel Pharmaceuticals position peaked at $10.8M in Q4 2025.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.